Abstract from Interim Report Q3-2009

ABSTRACT FROM INTERIM REPORT JANUARY-SEPTEMBER, Q3-2009

Read the full Abstract

THIRD QUARTER
• Net sales SKr 31.9 (25.4) million – increased 26 %
• EBITDA SKR 4.4 (2.0) million – improved with SKr 2.4 million
• Earnings before tax SKr 3.1 (0,7) million
• Net earnings SKr 2.1 (0.7) million
• Earnings per share SKr 0.10 (0.04)

YEAR-TO-DATE / FIRST NINE MONTHS
• Net sales SKr 92.6 (74.0) million – increased 25 %
• EBITDA SKr 7.7 (-2.4) million – improved with SKr 10.1 million
• Earnings before tax SKr 4.0 (0.9) million
• Net earnings SKr 25.0 (16.9) million*
• Earnings per share SKr 1.35 (0.84)
(* including deferred income tax SKr 22.0 (16.0) million)

BUSINESS PROGRESS
• Stable market development
• Continued strong sales increase with 26 % during Q3
• Substantial improvement of earnings, EBITDA margin was 11 % on an annual basis
• Successful marketing activity for Osstell, Attension and Q-Sense
• Strengthened sales and distribution organization globally, in the US and in China
• Good outlooks for full year 2009
• Rights issue of SKr 24 million to finance continued growth

CEO COMMENT
”During Q3-2009, a lot of things went our way. We have already reached the targets we set for full year 2009, on an annual basis. Our strong increase in net sales continued with 26 % during Q3. We have a high operational leverage which led to a strong improvement in our earnings, our EBITDA margin is now 11 % on an annual basis. Sales achievements during Q3 included orders from new key accounts such as Pfizer and from new geographical markets such as Saudi Arabia. We improved our short term prospects through successful marketing activities with Osstell, Q-Sense and Attension. Our strategic positions were also improved through important recruitments to our sales and distribution organization, along with the establishments of a representative office in China and sales office for Osstell in the US. The outlooks for the remainder of 2009 are stable. The decided rights issue creates good conditions for a strong development also in the longer term.” says Fredrik Lindgren, CEO of Biolin Scientific.